The faculty and researchers of the University of Chicago Medicine Comprehensive Cancer Center will present their research and clinical updates throughout the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH). For a full schedule of oral and poster presentations where our physicians and scientists are the speaker, chair or moderator download UCCCC […]
The FDA approved a breakthrough cancer treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin lymphoma, that uses genetically engineered immune cells to target cancer.
With a $4.7 million grant from the National Cancer Institute, UChicago’s Globus and cancer researchers at UChicago Medicine will build new protected cancer research networks that enable collaborations while keeping sensitive health data secure and private.
Three UChicago researchers received awards from the NIH High-Risk, High-Reward Research program to support innovative approaches to tackle major challenges in biomedical research.
A game-changing approach trains a young man’s immune system to defeat aggressive blood cancer.
The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.
Science Life spoke to Dr. Sonia Kupfer, Director of the GI Cancer Risk and Prevention Clinic, about why colon cancer cases are on the rise among young people.
UChicago Medicine to play key role in NIH-funded initiative that concentrates on genetic flaws related to pediatric cancer, birth defects.
A conversation with research specialist Larry House about his work and research experiences at UChicago.
A lifelong Notre Dame football fan’s journey as the first UChicago Medicine patient to receive a groundbreaking new cancer immunotherapy